Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, Gareth Morgan, David A. Cairns, Graham Jackson

Blood (2024) 144 (Supplement 1): 771.

https://doi.org/10.1182/blood-2024-208255

Published: 2024

Journal Articles

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Graham Jackson, Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, David A. Cairns, Gareth Morgan

Blood (2024) 144 (Supplement 1): 3375.

https://doi.org/10.1182/blood-2024-205871

Published: 2024

Journal Articles

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Charlotte Pawlyn, Faith E Davies, Gordon Cook, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Catherine Olivier, Anna Hockaday, John R Jones, Martin F Kaiser, Matthew W. Jenner, Walter Martin Gregory, Ruth M de Tute, Roger G Owen, Mark Drayson, David A. Cairns, Gareth Morgan, Graham Jackson

Blood (2024) 144 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2024-205788

Published: 2024